Apontis Pharma Forecast, price target & analysts
Apontis Pharma Target price 2025 - Analyst rating & recommendation
Apontis Pharma Classifications & Recommendation:
Apontis Pharma Price Target
| Target Price | €13.77 |
| Price | €10.80 |
| Potential |
27.50%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Apontis Pharma 2026 .
The average Apontis Pharma target price is €13.77.
This is
27.50%
register free of charge
€17.85
65.28%
register free of charge
€10.10
6.48%
register free of charge
|
|
| A rating was issued by 11 analysts: 1 Analysts recommend Apontis Pharma to buy, 2 to hold and 8 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Apontis Pharma stock has an average upside potential 2026 of
27.50%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million € | 48.47 | 58.83 |
| 31.14% | 21.38% | |
| EBITDA Margin | 7.22% | 12.31% |
| 134.80% | 70.48% | |
| Net Margin | 1.55% | 6.27% |
| 105.06% | 305.21% |
5 Analysts have issued a sales forecast Apontis Pharma 2025 . The average Apontis Pharma sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Apontis Pharma EBITDA forecast 2025. The average Apontis Pharma EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Apontis Pharma Analysts have issued a net profit forecast 2025. The average Apontis Pharma net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share € | 0.09 | 0.44 |
| 106.77% | 388.89% | |
| P/E | 24.40 | |
| EV/Sales | 1.31 |
5 Analysts have issued a Apontis Pharma forecast for earnings per share. The average Apontis Pharma EPS is
This results in the following potential growth metrics and future valuations:
Current Apontis Pharma Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| WARBURG RESEARCH GMBH |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| FIRST BERLIN EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Dec 02 2024 |
| WARBURG RESEARCH GMBH |
Locked
➜
Locked
|
Locked | Nov 06 2024 |
| HAUCK AUFHAEUSER INVESTMENT BANKING |
Locked
➜
Locked
|
Locked | Oct 17 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
WARBURG RESEARCH GMBH:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
FIRST BERLIN EQUITY RESEARCH:
Locked
➜
Locked
|
Dec 02 2024 |
|
Locked
WARBURG RESEARCH GMBH:
Locked
➜
Locked
|
Nov 06 2024 |
|
Locked
HAUCK AUFHAEUSER INVESTMENT BANKING:
Locked
➜
Locked
|
Oct 17 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
